Anthony Stein, MD, from the City of Hope, has conducted a first-in-human study to evaluate the safety and efficacy of…
Browsing: Acute Myelogenous Leukemia
Cell Death: Drug Combo Restores Signaling Ability of Leading Treatment for Blood Cancer Christina Glytsou PhD By Christina Glytsou, PhDAssistant…
Allogeneic Hematopoietic Cell Transplantation: How Can the ASAP Trial Help Relapsed or Refractory AML? Johannes Schetelig By Prof. Dr. med.…
Gemtuzumab Ozogamicin Enhances Outcomes in Intermediate Risk AML Patients Receiving Standard Induction Therapy: ASH 2022 Study Results Eunice Wang MD…
iFrame is not supported! Gemtuzumab Ozogamicin Enhances Outcomes in Intermediate Risk AML Patients Receiving Standard Induction Therapy: ASH 2022 Study…
Gemtuzumab Ozogamicin Enhances Outcomes in Intermediate Risk AML Patients Receiving Standard Induction Therapy: ASH 2022 Study Results Eunice Wang MD…
Myelodysplastic Syndromes Treatment Update for 2023 By Deepa Jeyakumar, MD from UCI Health I think what’s very exciting is that…
iFrame is not supported! Inotuzumab and MRD Understanding the Importance of Targeted Therapy in Cancer Treatment Summarized from Van Huynh,…
Myelodysplastic Syndromes Treatment Update for 2023 ASH AML Inotuzumab Update [Slides] – Kiran Naqvi, MD MOASC By Kiran Naqvi, MD…
2023 ASH AML Updates [Slides] – Kiran Naqvi MD – MOASC Acute myeloid leukemia updates from our recent ASH from…
iFrame is not supported! Notable Labs: Thomas Bock ASH 2022 The Future of AML Treatment By Thomas Bock, MD, MBA…
Notable Labs: Thomas Bock ASH 2022 The Future of AML Treatment By Thomas Bock, MD, MBA Where is the blood…
iFrame is not supported! Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician’s Choice…
A new maintenance option is available for AML, but are you proficient in identifying eligible patients? Dr. DiNardo and Dr.…
Yishai Ofran, MD, Director of Hematology department and Shaare Zedek Medical Center Jerusalem speaks about the ASH 2021 Abstract -…
Yishai Ofran, MD, Director of Hematology department and Shaare Zedek Medical Center Jerusalem speaks about the ASH 2021 Abstract -…
Courtney D. DiNardo, MD, MSCE, is a clinical researcher who focuses on prognostication and customized treatments for myeloid malignancies patients…
Courtney D. DiNardo, MD, MSCE, is a clinical researcher who focuses on prognostication and customized treatments for myeloid malignancies patients…
Karuppiah Kannan, Ph.D. Senior Director – Global Program Leader at Takeda Oncology speaks about the ASH 2021 Abstracts – 2488…
Karuppiah Kannan, Ph.D. Senior Director – Global Program Leader at Takeda Oncology speaks about the ASH 2021 Abstracts – 2488…
Naval Daver, MD from The University of Texas MD Anderson Cancer Center speaks about the ASH 2021 Abstract – 3426…
Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician’s Choice of Venetoclax in Combination…
Professor Andrew Wei is a haematologist at the Alfred Hospital and a Victorian Cancer Agency Research Fellow. Andrew has dual…
Professor Andrew Wei is a haematologist at the Alfred Hospital and a Victorian Cancer Agency Research Fellow. Andrew has dual…
Dr. Eunice Wang is the Director of the Roswell Park Comprehensive Cancer Center’s Leukemia Service. Dr. Wang joined the Roswell…
Dr. Eunice Wang is the Director of the Roswell Park Comprehensive Cancer Center’s Leukemia Service. Dr. Wang joined the Roswell…
Pamela J. Sung, MD from the Department of Medicine, Roswell Park Comprehensive Cancer Center speaks about ASH 2021 Abstract -…
Pamela J. Sung, MD from the Department of Medicine, Roswell Park Comprehensive Cancer Center speaks about ASH 2021 Abstract -…
CPI-613 (Devimistat) + Cytarabine + Mitoxantrone in Acute Myeloid Leukemia (AML) FDA Fast Track Designation CPI-613 (Devimistat) Demonstrates Positive Outcomes…
Jean-Jacques Kiladjian, M.D., Ph.D. from Saint-Louis Hospital and Paris Diderot University in France speaks about the ASH abstract – 481…
Eunice S. Wang, MD of Roswell Park Comprehensive Cancer Center discusses the ASH 2020 abstract – 27 Phase 3, Multicenter,…
Anthony S. Stein, MD of the City of Hope speaks about the ASH 2020 abstract – 192 Total Marrow and…
Nicholas J. Short, MD Assistant Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center…
Michael Kelly, MD, MPH, MS, Medical Director at Syros Pharmaceuticals discusses ASH 2020 abstract – 112 SY-1425, a Potent and…
Eunice Wang, MD of Roswell Park Comprehensive Cancer Center Genetic speaks about Testing + AML: New Resource to Bridge the…
Manisha H Shah, MD of The James Ohio State University Comprehensive Cancer Center explains the study: Dabrafenib, Trametinib, and IMRT…
Andrew Wei, MBBS, Ph.D. Alfred Hospital and Monash University U.S. Food and Drug Administration Approves Onureg® (azacitidine tablets), a New…
Andreas Burchert, MD University Hospital Giessen and Marburg Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia…
Christoph Röllig, MD discusses For Acute Myeloid Leukemia, Genetic Testing Is Often Worth the Wait
Keith W. Pratz, MD of Penn Medicine @PennMedicine discusses venetoclax plus azacitidine demonstratesstatistically significant overall survival benefit and improved remission…
Keith W. Pratz, MD of Penn Medicine @PennMedicine discusses venetoclax plus azacitidine demonstratesstatistically significant overall survival benefit and improved remission…
Keith W. Pratz, MD of Penn Medicine @PennMedicine discusses venetoclax plus azacitidine demonstratesstatistically significant overall survival benefit and improved remission…
Daniel Starczynowski, PhD of Cincinnati Children’s Hospital Medical Center @Cincy_Tech Kurome Therapeutics to develop therapies targeting cancer’s ability to evade…
Daniel Starczynowski, PhD of Cincinnati Children’s Hospital Medical Center @Cincy_Tech Kurome Therapeutics to develop therapies targeting cancer’s ability to evade…
Brian Jonas, MD, PhD of UC Davis Comprehensive Cancer Center @UCDavisHealth @ucdavis discusses timing of response to venetoclax combination treatment…
Brian Jonas, MD, PhD of UC Davis Comprehensive Cancer Center @UCDavisHealth @ucdavis discusses timing of response to venetoclax combination treatment…
Brian Jonas, MD, PhD of UC Davis Comprehensive Cancer Center @UCDavisHealth @ucdavis discusses timing of response to venetoclax combination treatment…
Lionel Ades, MD of St. Louis Hospital discusses the phase II study of pevonedistat + azacitidine vs. A in patients…
Lionel Ades, MD of St. Louis Hospital discusses the phase II study of pevonedistat + azacitidine vs. A in patients…